Component information
No US or EU label exists for this exact combination, so information is shown for each component.
Use: INDICATIONS AND USAGE Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. US FDA label
Use: INDICATIONS AND USAGE In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the… US FDA label
Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
Contraindications
- Jaundice
- Hypersensitivity to rifamycins or isoniazid
- Saquinavir/ritonavir, lurasidone, cabotegravir, fostemsavir, lenacapavir
- Manic or hypomanic psychosis
Dosing: Adult
- Tuberculosis, continuation phase (adults): Rifampicin about 10 mg/kg (450 to 600 mg) with isoniazid about 5 mg/kg once daily, on an empty stomach
Dosing: Altered kidney function
Rifampicin is mainly cleared by the liver, and isoniazid by acetylation (50% to 70% of a dose appears in urine). The Irish label gives no kidney dose adjustment for the fixed combination but warns that isoniazid can cause a cerebellar syndrome, mainly in chronic kidney disease, and peripheral neuropathy. Hemodialysis removes isoniazid (advised for refractory overdose). It has no US FDA label for the combination.
Kidney function measure: The SmPC does not grade kidney impairment; bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: rifampicin about 10 mg/kg (450 to 600 mg) with isoniazid about 5 mg/kg once daily, 30 minutes before or 2 hours after a meal (SmPC).
- CrCl 30–59 mL/min
- No kidney dose adjustment stated (SmPC). Pyridoxine for patients at risk of neuropathy.
- CrCl 15–29 mL/min
- No dose change for isoniazid or rifampicin at CrCl <30 (ATS/CDC/IDSA 2016; MSF); the SmPC asks for careful monitoring in severe renal dysfunction. Isoniazid can cause a cerebellar syndrome, mainly in chronic kidney disease, and peripheral neuropathy (slow acetylators, malnutrition); give pyridoxine and interrupt or reduce if neurotoxicity appears (SmPC 4.4). Pyrazinamide and ethambutol (separate products or 4-drug fixed-dose tablets) need thrice-weekly dosing at CrCl <30, so 4-drug fixed-dose tablets are unsuitable in CKD G4–G5 and on dialysis.
- CrCl <15 mL/min (not on dialysis)
- No dose change for isoniazid or rifampicin at CrCl <30 (ATS/CDC/IDSA 2016; MSF); the SmPC asks for careful monitoring in severe renal dysfunction. Isoniazid can cause a cerebellar syndrome, mainly in chronic kidney disease, and peripheral neuropathy (slow acetylators, malnutrition); give pyridoxine and interrupt or reduce if neurotoxicity appears (SmPC 4.4). Pyrazinamide and ethambutol (separate products or 4-drug fixed-dose tablets) need thrice-weekly dosing at CrCl <30, so 4-drug fixed-dose tablets are unsuitable in CKD G4–G5 and on dialysis.
- Hemodialysis (intermittent)
- No dose change for either drug (ATS/CDC/IDSA 2016); give after hemodialysis on dialysis days. Add pyridoxine; watch for neuropathy and cerebellar signs (SmPC 4.4). Pyrazinamide and ethambutol (separate products or 4-drug fixed-dose tablets) need thrice-weekly dosing at CrCl <30, so 4-drug fixed-dose tablets are unsuitable in CKD G4–G5 and on dialysis.
- Peritoneal dialysis
- No dose change (CrCl <30 guidance; ATS/CDC/IDSA 2016, MSF); pyridoxine; watch for neuropathy and cerebellar signs.
- CRRT
- No data; specialist input.
- Dialyzable? Isoniazid: yes (hemodialysis advised for refractory overdose). Rifampicin: not stated (about 80% protein-bound) (SmPC 4.9, 5.2).
- Monitoring Liver enzymes, bilirubin, creatinine, blood count and platelets at baseline; transaminases at least monthly if over 35 years, and every 2 to 4 weeks with liver disease or alcoholism. Neuropathy and cerebellar signs (especially CKD). Purpura or thrombocytopenia: stop rifampicin. Extensive enzyme-induction interactions (SmPC 4.4, 4.5).
Children (kidney dosing)
- eGFR ≥60
- No pediatric dosing or kidney data in the SmPC.
- eGFR 30–59
- No pediatric dosing or kidney data in the SmPC.
- eGFR 15–29
- No pediatric dosing or kidney data in the SmPC.
- eGFR <15 (not on dialysis)
- No pediatric dosing or kidney data in the SmPC.
- Hemodialysis (intermittent)
- No pediatric dosing or kidney data in the SmPC.
- Peritoneal dialysis
- No pediatric dosing or kidney data in the SmPC.
- CRRT
- No pediatric dosing or kidney data in the SmPC.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (April 2026). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- No pediatric dosing in this SmPC.
- Usual dose
- Not given (use single agents for weight-based pediatric dosing).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Film-coated tablet: 150 mg/75 mg, 300 mg/150 mg, 450 mg/400 mg
- Dispersible tablet: 75 mg/50 mg
- Tablet: 300 mg/150 mg
Registered products in the Philippines
28 products registered with the Food and Drug Administration (FDA) Philippines list Isoniazid + Rifampicin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products28
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
2-MaxRifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28’s (Box of 84’s) | RxVAT-exempt | Svizera Labs Private LimitedIndia | Diafarm Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited | DRP-8927-03 | Apr 5, 2037 | |
Bercurex-1Rifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletClear PVC/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | New Myrex Laboratories, Inc.Philippines | — | DRP-8632 | Jan 16, 2031 | |
BifixRifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletFlex Foil x 4's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY28918 | Jul 25, 2027 | |
DuasaphRifampicin + Isoniazid | 150 mg/ 75 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 6's (Box of 168's); Alu/Red PVC Blister Pack x 8's (Box of 80's); Alu/Red PVC Blister Pack x 9's (Box of 252's); Alu/Red PVC Blister Pack x 10's (Box of 30's and 100's); Alu/Red PVC Blister Pack x 12's (Box of 168's); Alu/Red PVC Blister Pack x 28's (Box of 84's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences Inc. | DRP-11021 | Dec 9, 2030 | |
Duasaph-300Rifampicin + Isoniazid | 300 mg/ 150 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 6's (Box of 168's); Alu/Red PVC Blister Pack x 8's (Box of 80's); Alu/Red PVC Blister Pack x 9's (Box of 252's); Alu/Red PVC Blister Pack x 10's (Box of 30's and 100's); Alu/Red PVC Blister Pack x 12's (Box of 168's); Alu/Red PVC Blister Pack x 28's (Box of 84's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences Inc. | DRP-10933 | Dec 9, 2030 | |
Duasaph-300Rifampicin + Isoniazid | 300mg/150mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 10's (Box of 100's); Alu/Red PVC Blister Pack x 28's (Box of 84's) | RxVAT-exempt | Bueno Salud Care (India) Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-14906 | Feb 7, 2029 | |
Duasaph-450Rifampicin + Isoniazid | 450 mg/400 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's and 10's (Box of x 4's and 10's (Box of 100's) Alu/Red PVC Blister Pack x 28's (Box of 84's) | RxVAT-exempt | Bueno Salud Care (India) Pvt. Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-13941 | May 22, 2028 | |
Duasaph-450Rifampicin + Isoniazid | 450 mg/400 mg Film-Coated TabletAlu/Red PVC Blister Pack x 4's (Box of 100's); Alu/Red PVC Blister Pack x 10's (Box of 100's); & Alu/Red PVC Blister Pack x 28's (Box of 84's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-14109 | Dec 11, 2030 | |
DuomaxRifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/Alu Blister Pack x 4's (Box of 80's); Alu/Alu Blister Pack x 28's (Box of 336's) for DOH TB Program; Alu/Alu Blister Pack x 28's (Box of 420's) for DOH TB Program; Alu/Alu Blister Pack x 14's (Box of 336's) for DOH TB Program | RxVAT-exempt | Lupin LimitedIndia | Multicare Pharmaceuticals Philippines, Inc.Importer: Lupin Philippines, Inc. | DRP-704-03 | Oct 29, 2028 | |
Fixcom 2Rifampicin + Isoniazid | 150 mg/ 75 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 80's); Alu/Clear PVDC Blister Pack x 28's (Box of 336's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DRP-15997 | Feb 10, 2030 | |
Fixcom 2Rifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's Box of 80's; Alu/Clear PVDC Blister Pack x 28's Box of 336's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Natrapharm, Inc. | DR-XY36417 | Feb 10, 2030 | |
Flamaway-2Rifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC blister pack x 28's (Box of 84's and 672's) | RxVAT-exempt | Svizera Labs Private LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited | DRP-8927-01 | Mar 6, 2037 | |
IfamsoRifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28's (Box of 84's); Alu/PVC-PVDC Blister Pack x 28's (Box of 672's) | RxVAT-exempt | Svizera Labs Private LimitedIndia | Ambica International CorporationTrader: Omnicals Pharma Private Limited | DRP-8927 | Jul 2, 2037 | |
Mac RHRifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/Amber-colored PVC/PE/PVDC blister pack x 28 tablets (Box of 84 tablets presented as 3 blister packs x 28 tablets) Alu/Amber-colored PVC/PE/PVDC blister pack x 28 tablets (Box of 672 tablets presented as 24 blister packs x 28 tablets) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY49620 | Feb 4, 2031 | |
Macox RH DTRifampicin + Isoniazid | 75 mg/50 mg Dispersible TabletAlu/Alu foil strip pack x 10 tablets (box of 100 tablets presented as 10 foil strip packs x 10 tablets) Alu/Alu foil strip pack x 28 tablets (box of 84 tablets presented as 3 foil strip packs x 28 tablets) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY49622 | Feb 4, 2031 | |
Macox RH DTRifampicin + Isoniazid | 75 mg/50 mg Dispersible TabletAlu/Alu foil strip pack x 10 tablets (box of 100 tablets presented as 10 foil strip packs x 10 tablets) Alu/Alu foil strip pack x 28 tablets (box of 84 tablets presented as 3 foil strip packs x 28 tablets) | RxVAT-exempt | Oxalis LabsIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY49623 | Feb 4, 2031 | |
Mixtreat-2Rifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28's (Box of 672's) | RxVAT-exempt | Svizera Labs Private LimitedIndia | Diafarm Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited | DRP-8927-04 | Jul 2, 2037 | |
Myrin IRifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/Rigid PVC/PVDC 250/100 Blister Pack x 10’s (Box of 80's); Alu/Rigid PVC/PVDC 250/100 Blister Pack x 28’s (Box of 336 tablets); Alu/Rigid PVC/PVDC 250/100 Blister Pack x 10’s (Box of 80's) [For DOH use only] | RxVAT-exempt | ICI Pakistan LimitedPakistan | Importer: Pfizer, Inc. | DRP-6598 | Feb 1, 2027 | |
NoneRifampicin + Isoniazid | 150 mg/75 mg Film-coated TabletAlu-Alu Blister Pack X 4's (Box of 80's); Alu-Alu Blister Pack x 28's for DOH TB Program (Box of 336's); Alu-Alu Blister Pack x 28's for DOH TB Program (Box of 420's); Alu-Alu Blister Pack x 14's (Box of 336's) | RxVAT-exempt | Lupin LtdIndia | UNILAB, Inc.Importer: Lupin Philippines, Inc. | DRP-704 | Oct 29, 2028 | |
NoneRifampicin + Isoniazid | 150mg/75mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 80's); Alu/Clear PVDC Blister Pack x 28's (Box of 336's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Patriot Pharmaceuticals CorporationTrader: Natrapharm, Inc. | DRP-15997-01 | Feb 10, 2030 | |
Philcox DuoRifampicin + Isoniazid | 150 mg/75 mg Film Coated TabletAlu/PVC Blister Pack x Pack x 10's (Box of 100's) | RxVAT-exempt | Huazhong Pharmaceutical Co., Ltd.China | Amb Hk Enterprises Inc. No. | DRP-16258 | Jan 10, 2030 | |
RimactazidRifampicin + Isoniazid | 300 mg/150 mg TabletBlister Pack x 10's (Box of 120's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Trader: Sandoz Philippines Corporation | DRP-5098 | Sep 29, 2030 | |
RimactazidRifampicin + Isoniazid | 450 mg/400 mg Film- Coated TabletBlister Pack x 10's (Box of 120's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Trader: Sandoz Philippines Corporation | DRP-5099 | Jun 7, 2030 | |
Surestep 2Rifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DR-XY43750 | Sep 25, 2029 | |
TB-2Rifampicin + Isoniazid | 150 mg/75 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 28’s (Box of 672's) | RxVAT-exempt | Svizera Labs Private LimitedIndia | Starpharm, Inc.Importer: Ambica International CorporationTrader: Omnicals Pharma Private Limited | DRP-8927-02 | Mar 2, 2037 | |
(no brand name)Rifampicin + Isoniazid | 150mg/75mg Film-Coated TabletAlu/PVC Blister Pack by 24's x 28's (Box of 672's) | RxVAT-exempt | Concept Pharmaceuticals Ltd.India | Medethix, Inc. | DRP-17441 | Dec 17, 2030 | |
(no brand name)Rifampicin + Isoniazid | 75mg/ 50mg Dispersible TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | S.M.H.P. Marketing & Consultancy | DR-XY48165 | Jul 5, 2027 | |
(no brand name)Rifampicin + Isoniazid | 75mg/ 50mg Dispersible Tablet100 tablets packed in LDPE bag enclosed in triple laminated sachet and kept in white opaque HDPE container with screw cap | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | S.M.H.P. Marketing & Consultancy | DR-XY48166 | Jul 5, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Saquinavir/ritonavir; lurasidone, cabotegravir, fostemsavir, lenacapavir | Avoid | Large falls in exposure or hepatotoxicity. | Contraindicated. |
| Hormonal contraceptives | Avoid | Contraceptive failure. | Use non-hormonal contraception during and for 2 weeks after. |
| Cyclosporine, tacrolimus, corticosteroids | Adjust or monitor | Large falls in levels (rejection risk; adrenal crisis). | Monitor levels closely; raise doses. |
| Warfarin, azole antifungals, phenytoin, many others | Adjust or monitor | Lower levels by enzyme induction (S-warfarin AUC down 74%). | Monitor INR or levels; adjust. |
| Clopidogrel | Avoid | More active metabolite; bleeding. | Discouraged. |
| Hepatitis C direct-acting antivirals | Avoid | Loss of effect. | Avoid. |
| Paracetamol, halothane | Adjust or monitor | More hepatotoxicity. | Caution; avoid halothane. |
| Antacids | Minor | Lower rifampicin absorption. | Give rifampicin at least 1 hour before. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Thrombocytopenia (rifampicin)
- Gastrointestinal upset
- Orange discoloration of body fluids
Serious
- Hepatitis (sometimes fatal; age-related with isoniazid)
- Peripheral neuropathy, cerebellar syndrome
- Thrombocytopenic purpura, disseminated intravascular coagulation
- Acute kidney injury (rifampicin)
- Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, acute generalized exanthematous pustulosis
- Anaphylaxis with intermittent dosing
Monitoring parameters
- Liver enzymes, bilirubin, creatinine, blood count and platelets at baseline; transaminases at least monthly if over 35 years, and every 2 to 4 weeks with liver disease or alcoholism. Neuropathy and cerebellar signs (especially CKD). Purpura or thrombocytopenia: stop rifampicin. Extensive enzyme-induction interactions (SmPC 4.4, 4.5). Kidney
- Liver tests (monthly over 35 years)
- Blood count and platelets
- Neuropathy signs; pyridoxine
Pharmacokinetics
Key PK parameters
| Half-life | Rifampicin about 3 hours (2 to 3 hours with repeated dosing); isoniazid levels halve within about 6 hours (acetylator-dependent) |
|---|---|
| Protein binding | Rifampicin about 80% |
| Metabolism (CYP, transporters) | Rifampicin hepatic (potent inducer); isoniazid by acetylation (genetic) |
| Renal excretion kidney | Rifampicin up to 30% in urine (half unchanged); isoniazid 50% to 70% in urine within 24 hours |
| Dialyzability kidney | Isoniazid yes; rifampicin not stated |
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Isoniazid + Rifampicin 75 mg + 150 mg Tablet | ₱4.00–₱8.00Reference ₱6.00 | per tablet | DPRI procurement range |
| 50 mg isoniazid + 75 mg rifampicin dispersible fixed-dose combination tablet (pediatric) | ₱7.25 | per tablet | PhilHealth GAMOT fixed fee |
| 75 mg isoniazid + 150 mg rifampicin tablet | ₱8.25 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Isoniazid + Rifampicin |
| PNF listing | Oral: 50 mg + 75 mg dispersible fixed dose combination tablet (pediatric)Restrictions: List B: in vivo bioequivalence studies required (PNF code B) |
| PNF listing | Oral: 75 mg + 150 mg tabletRestrictions: List B: in vivo bioequivalence studies required (PNF code B) |
| PhilHealth GAMOT | Yes (listed since October 13, 2026) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Rifinah 300/150 mg film-coated tablets SmPC (PA0540/068/002) [HPRA (Ireland) product information, April 2026; no US FDA label]. https://assets.hpra.ie/products/Human/17972/Licence_PA0540-068-002_10042026175715.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Sanofi-Aventis Ireland Limited. (2026). Rifinah 300/150 mg film-coated tablets (rifampicin/isoniazid) [Summary of product characteristics, licence PA0540/068/002; text revised April 2026]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/17972/Licence_PA0540-068-002_10042026175715.pdf
- Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., Higashi, J. M., Ho, C. S., Hopewell, P. C., Keshavjee, S. A., Lienhardt, C., Menzies, R., Merrifield, C., Narita, M., O'Brien, R., . . . Vernon, A. (2016). Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: Treatment of drug-susceptible tuberculosis. Clinical Infectious Diseases, 63(7), e147–e195. https://doi.org/10.1093/cid/ciw376
- Médecins Sans Frontières. (n.d.). Tuberculosis: Practical guide for clinicians, nurses, laboratory technicians and medical auxiliaries. Appendix 12: Dose adjustments in renal insufficiency. Retrieved November 17, 2026. https://medicalguidelines.msf.org/en/viewport/TUB/english/appendix-12-dose-adjustments-in-renal-insufficiency-20324400.html
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .

